The National Institute on Drug Abuse (NIDA) awarded a $770,751 Project Grant under the Drug Use and Addiction Research Programs (CFDA 93.279) to the Oregon Health & Science University (OHSU) with a period of performance from July 1, 2025 to March 31, 2030. The grant supports research to examine the impact of telehealth expansion on access to and utilization of opioid use disorder (OUD) treatment within community health centers (CHCs). The study will use over 10 years of electronic health...
This Project Grant award of $1,749,422.00, provided by the Centers for Disease Control and Prevention's National Center for Injury Prevention and Control under CFDA 93.136 Injury Prevention and Control Research and State and Community Based Programs, aims to evaluate the role of telehealth in buprenorphine treatment initiation, retention, overdose mortality, and access equity. The primary awardee, The General Hospital Corporation (doing business as Massachusetts General Hospital), will...
This Project Grant award of $594,122, provided by the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279), supports the development and testing of telehealth workflows and technologies to increase access to buprenorphine treatment for opioid use disorder in vulnerable settings. The award recipient, Boulder Care, Inc., will partner with Sano Health and the National Survivors Union to provide smartphones and connectivity to people in high-risk...
This Project Grant award from the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279) provides $844,475 to the University of Alabama at Birmingham (UAB) to test a bundled intervention aimed at increasing treatment uptake for patients with opioid use disorder (OUD) and nonfatal opioid overdoses after emergency department (ED) discharge. The proposed intervention combines telehealth, peer support, buprenorphine prescribing, and linkage to...
The National Institute on Drug Abuse (NIDA), under the federal Drug Use and Addiction Research Programs (CFDA 93.279), awarded a $460,432 Project Grant to the Regents of the University of Minnesota to develop and pilot a comprehensive telehealth program at syringe service programs (SSPs) to engage people who inject drugs (PWID) into the HIV care continuum. The key products and services to be delivered include: Conducting formative research to understand determinants of HIV and addiction among...
This Project Grant award from the National Institute on Drug Abuse (CFDA 93.279 - Drug Use and Addiction Research Programs) provides $541,080 to The Trustees of Columbia University in the City of New York to conduct a randomized controlled trial examining the use of extended-release injectable buprenorphine versus sublingual buprenorphine/naloxone in treating opioid use disorder (OUD) among individuals who use high-potency synthetic opioids. The key objectives are to compare abstinence and...
This federal Project Grant award of $4,665,000 was provided by the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279) to the University of Washington. The award will fund the development and testing of a novel "Community-Based Opioid Treatment (CBOT)" implementation strategy to deliver buprenorphine for opioid use disorder treatment and HIV prevention/care services to people who use opioids. The project will involve two parts -...
The National Institute on Drug Abuse (NIDA) awarded a $445,000 Project Grant under the Drug Use and Addiction Research Programs (CFDA 93.279) to The Children's Hospital Corporation, doing business as Boston Children's Hospital. The grant will fund the development and pilot testing of a novel telehealth and mobile health intervention called MOMENT-V to address cannabis use disorder in young adults seen in primary care. The intervention combines motivational enhancement therapy delivered via...
The National Institute on Drug Abuse (NIDA) awarded a $2,729,018 Project Grant under the Drug Use and Addiction Research Programs (CFDA 93.279) to the University of Rhode Island. The purpose of this 2-year award, with a start date of September 15, 2024, is to rigorously develop and evaluate a mobile health intervention for adults with co-occurring opioid use disorder (OUD) and post-traumatic stress disorder (PTSD) during community re-entry after residential OUD treatment. The proposed mobile app...
This federal Project Grant award of $459,045, provided by the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279), is for a study titled "The Cascade of Care for Patients with Opioid Use Disorder Identified Through a Large Public Health System." The study aims to modify the existing Opioid Use Disorder (OUD) Cascade of Care model to better reflect the changing landscape of real-world OUD treatment, enabling critical research...
This Project Grant award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), provides $2,930,360 to evaluate the real-world effectiveness of telehealth-delivered buprenorphine (tele-buprenorphine) for treating opioid use disorder (OUD). The study will use national data from the Veterans Health Administration and Medicaid to compare the effectiveness of tele-buprenorphine to in-person care, including for high-risk and high-need populations. The project will employ novel "emulated target trial" methods and incorporate stakeholder perspectives to develop consensus guidance on optimizing tele-buprenorphine care. Key sub-awards went to Boston Medical Center Corporation ($XX) and the RAND Corporation ($XX) to support the research and analysis. This project aims to generate critical insights to inform best practices and policies for improving real-world OUD treatment through telehealth.